A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses
- Authors
- Kim, Na-Eun; Kim, Mun-Jin; Park, Bum Ju; Kwon, Jung Won; Lee, Jae Myun; Park, Jung-Hwan; Song, Yoon-Jae
- Issue Date
- Feb-2024
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Human norovirus; DNA vaccine; VP1; Immunogenicity
- Citation
- VACCINE, v.42, no.6, pp 1392 - 1400
- Pages
- 9
- Journal Title
- VACCINE
- Volume
- 42
- Number
- 6
- Start Page
- 1392
- End Page
- 1400
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91594
- DOI
- 10.1016/j.vaccine.2024.01.090
- ISSN
- 0264-410X
1358-8745
- Abstract
- Human noroviruses (HuNoVs) are highly contagious and a leading cause of epidemics of acute gastroenteritis worldwide. Among the various HuNoV genotypes, GII.4 is the most prevalent cause of outbreaks. However, no vaccines have been approved for HuNoVs to date. DNA vaccines are proposed to serve as an ideal platform against HuNoV since they can be easily produced and customized to express target proteins. In this study, we constructed a CMV/R vector expressing a major structural protein, VP1, of GII.4 HuNoV (CMV/R-GII.4 HuNoV VP1). Transfection of CMV/R-GII.4 HuNoV VP1 into human embryonic kidney 293T (HEK293T) cells resulted in successful expression of VP1 proteins in vitro. Intramuscular or intradermal immunization of mice with the CMV/ R-GII.4 HuNoV VP1 construct elicited the production of blocking antibodies and activation of T cell responses against GII.4 HuNoV VP1. Our collective data support the utility of CMV/R-GII.4 HuNoV VP1 as a promising DNA vaccine candidate against GII.4 HuNoV.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91594)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.